Ethos Technologies Inc. (LIFE)
| Market Cap | 947.29M |
| Revenue (ttm) | 344.06M +115.4% |
| Net Income | 56.14M +3,223.7% |
| EPS | 0.96 +3,104.0% |
| Shares Out | 62.94M |
| PE Ratio | 15.66 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 963,506 |
| Open | 17.50 |
| Previous Close | 16.85 |
| Day's Range | 15.05 - 17.80 |
| 52-Week Range | 15.05 - 19.00 |
| Beta | 1.19 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About LIFE
Ethos Technologies Inc. provides third-party administrator services for insurance policies in United States, India, and Singapore. The company offers Ethos, a three-sided technology platform that transforms the buying, selling, and risk management experience of life insurance for consumers, agents, and carriers. Its products include term life insurance, whole life insurance policies, and indexed universal life insurance. The company also provides wills and estate planning; and supplemental health insurance products. It serves consumers, agents,... [Read more]
News
Ethos Technologies: A Surprisingly Soft Debut
Ethos Technologies: A Surprisingly Soft Debut
Insurance platform Ethos Technologies valued at $1.2 billion in Nasdaq debut
Ethos Technologies clinched a valuation of $1.2 billion in its Nasdaq debut on Thursday, adding to a wave of insurance companies capitalizing on buoyant investor demand.
Ethos Announces Pricing of Initial Public Offering
AUSTIN, Texas, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced the pricing of its initial pub...
Ethos Technologies prices US IPO at $19/share, Bloomberg News reports
Insurance platform Ethos Technologies priced its U.S. initial public offering at $19 per share, Bloomberg News reported on Wednesday, citing a person familiar with the matter.
U.S. IPO Weekly Recap: Equipment Rental Rises While Crypto Company Crashes In 2-IPO Week
Two operating companies priced IPOs this week, along with six SPACs. Ten issuers submitted initial filings this week, with five operating companies and five SPACs. Four IPOs are currently scheduled in...
Ethos and North American Collaborate to Offer Accumulation Indexed Universal Life Product
AUSTIN, Texas and DES MOINES, Iowa, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced a partner...
U.S. IPO Weekly Recap: Small Issuers And SPACs Join The Pipeline In Short Holiday Week
Seven IPOs and two SPACs submitted filings this week; no pricings this week. The IPO calendar looks quiet for the week ahead, with one small issuer tentatively slated to debut. Street research is expe...
Ethos and Aflac Partner to Bring Supplemental Health Product Suite to Independent Distribution
Ethos announced a partnership with Aflac to expand access to Aflac's supplemental insurance policies through Ethos's digital distribution platform.
Ethos Technologies Targets IPO Amid Positive Insurance Offerings
Ethos Technologies Inc. has filed for a $100 million IPO and provides a three-sided digital life insurance marketplace platform. LIFE is growing rapidly and profitably, with strong revenue, gross marg...
Ethos Files Registration Statement for Proposed Initial Public Offering
AUSTIN, Texas, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced that it filed a registration ...
Insurtech Leader Ethos Adds Industry Veteran William Wheeler to Board of Directors
AUSTIN, Texas, July 30, 2025 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced the appointment of William J. ...
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-cla...
aTyr Pharma to Present Poster Describing Efzofitimod's Mechanism of Action at the American Thoracic Society 2024 International Conference
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class ...
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
Independent data and safety monitoring board (DSMB) recommends continuation of study without any modifications. Findings further support favorable safety profile of efzofitimod.
aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment in the second quarter of 2024. Ended the first quarter 2024 with $87.7 million in cash, cash equivalents...
aTyr Pharma, Inc. (LIFE) Q4 2023 Earnings Call Transcript
aTyr Pharma, Inc. (LIFE) Q4 2023 Earnings Call Transcript
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment in the second quarter of 2024. Company launches Individual Patient Expanded Access Program (EAP), all...
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its prop...
aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
Individual Patient EAP allows access to efzofitimod for patients who complete the Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis. Company initiating program based on blinded EFZO-FIT™ study investig...
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor for efzofitimod program in interstitial lung disease (ILD).
aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023
Efzofitimod demonstrated immune regulatory function improving disease outcomes and mitigating fibrosis in animal models. Efzofitimod demonstrated immune regulatory function improving disease outcomes ...
aTyr Pharma to Present at November Investor Conferences
SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its prop...
aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes
Post-hoc analysis from Phase 1b/2a study in pulmonary sarcoidosis presented at the European Respiratory Society (ERS) International Congress 2023.
aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA ...